Korean J Gastroenterol.  2021 May;77(5):261-262. 10.4166/kjg.2021.062.

The Efficacy of Immune Checkpoint Inhibitors as First-line Treatment in Microsatellite-instability-high Metastatic Colorectal Cancer

• Lee JY

• KMID: 2516045
• DOI: http://doi.org/10.4166/kjg.2021.062

Reference

1. André T, Shiu KK, Kim TW, et al. 2020; Pembrolizumab in microsatelliteinstability-high advanced colorectal cancer. N Engl J Med. 383:2207–2218. DOI: 10.1056/NEJMoa2017699. PMID: 33264544.

2. 2021. NCCN clinical practice guidelines in oncology. [Internet]. National Comprehensive Cancer Network;Pennsylvania (IL): Available from: https://www.nccn.org/professionals/physician_gls/pdf/colon.pdf. cited 2021 Jan 21.

3. de la Chapelle A. 2003; Microsatellite instability. N Engl J Med. 349:209–210. DOI: 10.1056/NEJMp038099. PMID: 12867603.

4. Tougeron D, Sueur B, Zaanan A, et al. 2020; Prognosis and chemosensitivity of deficient MMR phenotype in patients with metastatic colorectal cancer: an AGEO retrospective multicenter study. Int J Cancer. 147:285–296. DOI: 10.1002/ijc.32879. PMID: 31970760.

5. Innocenti F, Ou FS, Qu X, et al. 2019; Mutational analysis of patients with colorectal cancer in CALGB/SWOG 80405 identifies new roles of microsatellite instability and tumor mutational burden for patient outcome. J Clin Oncol. 37:1217–1227. DOI: 10.1200/JCO.18.01798. PMID: 30865548. PMCID: PMC6506418.

6. Le DT, Durham JN, Smith KN, et al. 2017; Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science. 357:409–413. DOI: 10.1126/science.aan6733. PMID: 28596308. PMCID: PMC5576142.

7. Le DT, Kim TW, Van Cutsem E, et al. 2020; Phase II open-label study of pembrolizumab in treatment-refractory, microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: KEYNOTE-164. J Clin Oncol. 38:11–19. DOI: 10.1200/JCO.19.02107. PMID: 31725351. PMCID: PMC7031958.